It’s more than just being Fragile : How to Handle Potent Formulation?

Sep 25, 2017

Many modern medicines are highly potent, with only tiny doses required to achieve a therapeutic effect. But a nanomolar medicine poses extra hazards during manufacturing, whether the product is a biologic or a small molecule. These issues have to be evaluated and addressed in the design of a manufacturing facility for such products. Not only is it vital that the product not become contaminated, but employees and the general public must be protected from the product. Exposure to just a small quantity of a highly potent compound can pose significant health risks.

Highly potent products have their individual manufacturing requirements. But the issues pertaining to safe handling are often common and not product specific. Potency is often a function of structural class, but it cannot be predicted for new molecules or new biological products without sufficient testing. A dramatic increase in development of new drugs, particularly in oncology, is more likely to require engineering controls for containment. Proper handling of these materials involves specialized facilities that are carefully designed to minimize containment risks.

Facility Design

Some facility design requirements are common to all product types. Most significant type of facility design is known to be as process isolation. In this process, enclosed equipment such as sealed reactors and dryers are utilize for product transfer systems, thus, for moving materials through a process train. A facility should also be designed with equipment such as isolators, laminar flow hoods, and local exhaust ventilation appropriate for potent compound handling.

Airflow within the facility should be single pass to prevent cross-contamination or concentration of materials. Exhaust air should be filtered to ensure that escaping product is captured before its release to the external environment. In addition, proper air-pressure differentials must be established to keep potent compound–handling areas negative to all adjacent vestibules or airlocks. Equipment and facility engineering controls apply not only to the manufacturing areas, but also support areas such as process development and quality control laboratories.

Even with extensive engineering controls, personnel working with potent compounds should wear suitable personal protective equipment (PPE), including respiration equipment for those working around the most potent products. Proper training on procedures for operation and maintenance of containment and isolation equipment is critical. Staff members must understand why the use of engineering controls is crucial for a manufacturing process.

Product Categories

Before work begins on any drug product, it must be evaluated and characterized to assess potential hazards. For contract manufacturers, the first call is clearly to the customer, who should have information about a product’s safety and toxicology. Other information can be gleaned by making comparisons with similar products with known toxicological properties. The drug is then categorized according to its potential hazards so correct handling procedures can be established.

The performance-based exposure control limits (PBECL) categorization system links compound toxicity and potency to procedures for safe handling practices. This system was established in the late 1980s by health and safety departments within large pharmaceutical companies working on development projects for which insufficient data were available to determine occupational exposure limits (OELs). The industry uses many different categorization systems — including three, four, and five-tier systems — but this most common system has four categories.

Category 1 compounds are low potency with higher dosage levels. They have minimal acute or chronic health effects and good warning properties. These products will have no genetic effects and will not be sensitizers. Absorption will be slow, and no medical intervention will be required following exposure to them.

Category 2 compounds have moderate acute or chronic toxicity, but their effects are reversible. They may be weak sensitizers. Most have fair warning properties, a moderate absorption rate, and no genic effects, but medical intervention may be required after exposure to them.

Category 3 compounds have elevated potency, with high acute or chronic toxicity. These effects may be irreversible. The products may be moderate sensitizers, and their warning properties are likely to be poor or absent. Their absorption rates may be rapid, they may have suspected or known genic effects, and moderate to immediate medical intervention will be required. At SAFC Pharma, we consider this to be the default category.

Category 4 compounds have high potency and extreme acute and chronic toxicity. They cause irreversible effects and are likely to be strong sensitizers, with poor or no warning properties and a rapid absorption rate. These products will have known genetic effects and require a higher degree of medical intervention. They may also affect sensitive subpopulations to a greater extent than the public overall.

All potent products fall into category 3 or 4, depending on their cumulative risk factors. Requirements for containment and protection vary among the categories, and the precise ways they are put into practice differ. The details depend on whether a product is an infectious biologic such as a viral vector or vaccine, a highly potent small molecule (made by chemical reaction or fermentation), or an antibody drug conjugate that links a biologic to a potent small molecule.

Containment of Hazards

A facility manufacturing a high-potency active pharmaceutical ingredient (API) will resemble a standard API manufacturing plant, but it will house additional containment equipment (such as isolators and single air-pass systems) and facility engineering controls. For nonhazardous chemicals, ingredients can usually be added to an open reactor. For highly potent compounds, they cannot. To prevent escape, everything must be sealed throughout the manufacturing process, from raw material addition to the reactor through to the packaging of a final product.

For a category 1 molecule — which offers little risk during manufacturing — generally safe laboratory practices and gowning are sufficient. Open handling may be acceptable for small quantities of product, but local ventilation is advisable for handling larger quantities. However, no containment is needed. Standard laboratory practices and gowning are enough for category 2 as well, but the cut-off point for local ventilation is lower, and containment is needed for high-energy, dust-generating operations such as milling.

If a molecule falls into category 3, then it requires high-potency manufacturing methods. Operators need additional gowning and respiratory protection when handling powders, which should not be handled openly. Although small quantities of such products can be handled within a laminar-flow enclosure, processing at large scale presents more complex challenges. Operators wear protective clothing, but process isolation equipment is the primary control at our company. Additional facility controls need to be in place for containment, notably closed-system solution and solid transfers, even at glassware scale. Material handling takes place in an isolator glove box, and charge bottles are filled with raw materials, which are added to reactors through closed-system technologies such as α–β valves.

Category 4 products (the most hazardous) require full gowning and supplied-air respiratory protection in a specialized facility in addition to all the requirements for category 3. In addition to full containment of all solutions and powders as well as restrictions against open handling, deactivation and/or verifiable dissolution and rinsing are required for cleaning.

Using process isolation and containment equipment is the most important means of protection. By ensuring that an entire manufacturing process is carried out in closed systems — from raw materials to product packaging — the chances of employee exposure can be minimized.

Requirements for Different Product Types

Many general requirements for chemical API plants are the same for facilities manufacturing highly potent biologics, but there are some important differences. Viral vectors and vaccines are manufactured in sealed bioreactors, and because they are infectious, these products must be carefully contained. Operators and the public must be protected in the event of an escape. As with chemical facilities, air should be single-pass and HEPA-filtered, with each manufacturing suite exhausting separately through further HEPA filters to prevent cross-contamination. People, equipment, and raw materials should all flow from clean to dirty areas, with exit vestibules providing the final line of containment.

TideCell® High Density bioreactor system is the extended large scale system of the lab scale CelCradle® bioreactor system. In this system, a matrix vessel is packed with porous BioNoc™ II carriers and functions as an artificial lung with huge contact surface for nutrition and aeration.

Cross-contamination is an even greater issue with virus-based products. One means of prevention is the use of disposable bioreactors with a minimum of hard piping. This eliminates the problem of infectious materials remaining inside bioreactors after cleaning and sterilization. Each reactor itself is sealed once a process is finished and product isolated, and the remains are disposed of as a biohazard. Single-use technology might seem to add cost through consumables, but it removes the need for cleaning and validation, which allows much faster changeover between different products. That’s particularly important in multipurpose facilities that produce many different viruses and vaccines.

CelCradle™ is a disposable bioreactor capable of high-density cell culture for protein expression, virus, and monoclonal antibody production. It is designed based on the concept of bellow-induced intermittent flow of media and air through porous matrices, where cells reside. This provides a low shear, high aeration, and foam-free culture environment.

An antibody–drug conjugate combines an antibody that targets a specific site in a patient’s body with a small-molecule payload that provides a therapeutic effect. As high-potency small molecules become more frequent in bioconjugates, containment issues become crucial. Not only do the chemical issues have to be considered, but manufacturing the antibodies also requires a biologic facility — and biologic and chemical facilities have very different requirements. Facilities designed for conjugating antibodies to small-molecule potent compounds must combine the two facility types to ensure that containment, cleaning, and proper aseptic handling techniques are incorporated.

It makes more sense when designing a facility for manufacture of antibody–drug conjugates to introduce chemical handling capabilities into a facility designed for biological manufacturing rather than vice versa. This can be done by installing a containment isolator (complete with airlock, rapid transfer port, and utility connection plate) into an aseptic environment that also contains a biological safety cabinet and other equipment necessary for biologics. Essentially, introducing all the equipment for high-potency API manufacture within a biologics facility adds greatly to its complexity.

Secondary metabolites involve current good manufacturing practice (CGMP) compliant manufacture of highly potent small-molecule drugs using biologic systems, generally organisms such as yeast or fungi. A growing number of APIs and advanced intermediates are being manufactured in bioreactors. Just like small-molecule pharmaceutical chemical products, their containment issues depend on the precise nature of each chemical, so a full assessment must first be carried out to evaluate the risks. If the purified product poses enough risk, then purification process will need to be carried out under containment.

Containment Barrier Isolator (CBI) integrated with a Biological Safety Cabinet (BSC) made out of full stainless steel

If a secondary metabolite product is highly potent, then a combination of biological-and chemical-enhanced containment will be necessary, with level 2 large-scale biological safety alongside the ability to isolate highly potent compounds up to category 4. Each separate manufacturing suite will require single-pass HEPA air supply and separate exhaust complete with room pressure differentials and full airlocks and vestibules around each manufacturing suite as well as directional flow (from clean to dirty) of personnel, materials, and waste. For multipurpose facilities of this type, strict changeover procedures must be observed using automated steam-and clean-in-place (SIP and CIP).

Other News


Raising Your Standards with Esco Downflow Booth
Airflow Containment on Its Best

Date: Nov 29, 2017


Bio-decontamination Within
The Efficiency of Esco BioVap™ Inside the Isolators

Date: Nov 28, 2017


Esco Pharma GB exhibited at CPhI and P-Mec in Germany

Date: Nov 08, 2017


Survivor 101: Safe Change Filtration

Date: Nov 07, 2017


The Horror Behind the Gross Art of Sneeze and Cough

Date: Oct 27, 2017


Esco Life Sciences and Healthcare is Strengthening its Core in Biocontainment

Date: Oct 18, 2017


Esco Pharma is at Two Places at Once

Date: Oct 05, 2017


A Perfect Mate

Date: Sep 27, 2017


Nanotechnology: Containment Strategies and Engineering Controls

Date: Sep 26, 2017


Innovative Solutions for the Next Generation: Esco Pharma at ISPE 2017

Date: Aug 30, 2017


How SAFE is your FOOD?

Date: Aug 30, 2017


Nanotechnology in Pharmaceutical R&D: Drug Delivery System

Date: Jul 25, 2017


Inhaled Insulin: Boon or Bane?

Date: Aug 11, 2017


Esco Pharma at High Potent Medicines Conference 2017

Date: Jun 21, 2017


Quality Assurance System

Date: Jun 16, 2017


Defects

Date: Jun 16, 2017


Esco Pharma GB is moving!

Date: May 30, 2017


Esco Pharma at INTERPHEX 2017

Date: Apr 04, 2017


Esco Isoclean® Isolators Aid in a Pharmacy Compounding Facility in Singapore

Date: Mar 17, 2017


Esco Pharma Advancing Aseptic Pharmaceutical Processing with SP Scientific PennTech and ESS Technologies

Date: Jan 26, 2017


Esco joins the biggest pharma event in South Asia!

Date: Nov 28, 2016


Feeling Alienated by Safety?

Date: Dec 01, 2016


Blow-Fill-Seal Technology and Isolators

Date: Nov 22, 2016


How Clean is Clean Enough?

Date: Nov 08, 2016


Why isolators are still preferred when handling HPAPIs?

Date: Oct 27, 2016


Be SAFE in Handling High Potency APIs

Date: Oct 26, 2016


Cytotoxic Drugs: Safe Handling in the Workplace!

Date: Oct 17, 2016


Esco isolator finally arrives in the land of the rising sun

Date: Sep 26, 2016


Esco Healthcare exhibits at the 16th ISPE – Singapore Affiliate

Date: Sep 16, 2016


Unidirectional or Turbulent Airflow: Which is best for Sterile Pharmacy Compounding?

Date: Sep 01, 2016


Discover the most diverse compounding pharmacy isolators

Date: Aug 18, 2016


The need for engineering controls in preventing compounding pharmacy mishaps

Date: Jul 19, 2016


Esco at the ASHP in Baltimore!

Date: Jun 23, 2016


Esco at the 2016 PPhA National Convention in Cebu City

Date: Jun 01, 2016


Esco Pharma ships out General Processing Platform Isolator (GPPI) to a client in Canada

Date: Jan 04, 2016


Esco Launches VacciXcell and TapestleRx

Date: Dec 03, 2015


VacciXcell commences the 1st day of exhibition at the Europe Vaccine Congress 2015 in Madrid

Date: Nov 10, 2015


Esco Pharma exhibited concurrently in Pharma Expo Las Vegas and IPEX Packaging Expo in Jakarta

Date: Oct 07, 2015


Esco Pharma partners with UP College of Pharmacy

Date: Jul 09, 2015


Thank you for visiting Esco at ACHEMA 2015!

Date: Jun 26, 2015


Esco at ISPE Exhibition

Date: Jun 09, 2015


Esco Pharma is Proud to Launch its New Range of Containment Isolators

Date: Apr 28, 2015


Esco GB Ltd hosted the 2014 Training at its new premises in Barnsley

Date: Dec 15, 2014


Esco Pharma at ISPE Event in Singapore.

Date: Aug 13, 2014


Esco at INTERPHEX 2014!

Date: Jul 17, 2014